Deerfield Beach, Florida, November 23, 2020 – OTC PR WIRE — CYIOS Corp. (OTC US: CYIO), a publicly traded company focused on developing and marketing specialty branded products in the Health and Wellness markets, is pleased to announce it has received approval from Amazon to sell various My-shield sanitizing products in Amazon’s Personal Safety and Household category. Products to be sold on Amazon.com will include the My-shield triple play sanitizing products which have recently undergone clinical studies for effectiveness including My Shield Hand Sanitizer, My-shield Surface Cleaner and My-shield Laundry Complete. Clinical data from these studies conducted on this trio of My-shield sanitizing products have shown long lasting sanitizer protection and effectiveness against a surrogate virus for SARS-CoV-2 on skin, hard surfaces, fabrics and clothes.
John O’Shea CYIO’s Chairman stated, “We are pleased to have received this approval to sell various My-shield sanitizing products in Amazon’s Personal Safety and Household category. Our strategy continues to be on developing market and distribution opportunities around a Triple Play of sanitizing products which have recently undergone clinical studies for effectiveness including My Shield Hand Sanitizer, My-shield Surface Cleaner and My-shield Laundry Complete. During the six week period of time we had to undergo for the approval process within this product category, several of the My-shield Zetrisl® based sanitizer products had completed lengthy clinical testing in a laboratory setting and showed effectiveness against a CDC recognized surrogate virus for SARS-CoV-2 on skin, hard surfaces, fabrics and clothes. Results of which are posted here: Zetrisil-The-Total-Covid-19-Solution
Approval on Amazon gives the Company an additional platform for selling direct to consumers, which complements our recently announced launch with RangeMe giving us direct access to thousands of retail purchasing managers on their B2B platform. As we enter the holiday season, keep an eye out for valuable holiday specials, product marketing and advertising on the My-shield Triple Play and our “24” Brand Hand sanitizer which is also Zetrisl® powered. We believe giving the gift of safety and security with these long-lasting clinically proven sanitizers for effectiveness is a terrific and thoughtful holiday gift”.
About Zetrisil: Zetrisil®-based technologies are a family of proprietary silicon-based virus killing agents that reduce the presence of the virus from the hands, hard surfaces, fabric and most clothing environments. Zetrisil® effectively protects and/or “shields” the area that “24” Brand hand sanitizer and My-shield products are applied to from bacterial contamination for an extended period of time after application. Made with non-alcohol, Benzalkonium Chloride (BZK), My-shield® and 24 Brand sanitizers are a safer alternative to Alcohol-based hand sanitizers which can be absorbed into the bloodstream, are flammable, and are only proven effective for a few minutes after each application. These factors make traditional alcohol-based hand sanitizers a less than optimal choice particularly for families with children and/or for those out and about in public. Because Zetrisil® is safer than traditional agents and remains on the skin for several hours, people are protected longer without the need for frequent applications of sanitizer ― all without the toxicity and flammability concerns of alcohol-based sanitizers. The recent clinical testing data is powerful and proven evidence of the effectiveness of these products.
Investors are encouraged to follow CYIOS using:
About ChoiceWellness, Inc:
ChoiceWellness, Inc. is a health and wellness company that has brought to market the DR’s CHOICE line of products, as well as the “24” Brand Hand Sanitizer products. DR’s CHOICE was developed with a mission to offer Doctors and Medical Practitioners their own Professional Grade CBD BRAND with a suite of products they could stand behind and be confident to offer to their patients. Our customers can be assured that DR’s CHOICE CBD products have gone through the highest scrutiny of testing for purity, potency and quality. DR’s Choice products have been brought to market for Doctors and Medical Professionals seeking a better solution for patients suffering from pain, inflammation, anxiety or other persistent symptoms. For more information please visit www.choicewellnessbrands.com
About CYIOS Corporation
CYIOS Corporation is a publicly traded company focused on developing and marketing specialty branded products in the Health and Wellness markets, including the “DR’s CHOICE” and “24” brand of products. The team has in-depth knowledge of the health and wellness markets, financial services industry, medical and health services, and blockchain. The Company looks to develop, distribute, and license proprietary products as well as evaluate potential acquisition opportunities. Further, the Company continues to seek and evaluate attractive business opportunities and to leverage its resources and expertise to build a diversified, sustainable business model. For more information please visit www.cyioscorporation.com
FORWARD-LOOKING STATEMENTS: This release contains “forward-looking statements.” Forward-looking statements also may be included in other publicly available documents issued by the Company and in oral statements made by our officers and representatives from time to time. These forward-looking statements are intended to provide management’s current expectations or plans for our future operating and financial performance, based on assumptions currently believed to be valid. They can be identified by the use of words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “would,” “could,” “will” & other words of similar meaning in connection with a discussion of future operating or financial performance. Examples of forward-looking statements include, among others, statements relating to future sales, earnings, cash flows, results of operations, uses of cash and other measures of financial performance. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and other factors that may cause the Company’s actual results and financial condition to differ materially from those expressed or implied in the forward-looking statements. Such risks, uncertainties and other factors include, among others such as, but not limited to economic conditions, changes in the laws or regulations, demand for products and services of the company, the effects of competition and other factors that could cause actual results to differ materially from those projected or represented in the forward-looking statements. Any forward-looking information provided in this release should be considered w/ these factors in mind. We assume no obligation to update any forward-looking statements contained in this report.
Perspectum Announces World’s 1st Integrated Imaging Service for Long Covid Is Approved by UK’s MHRA
January 14, 2021
The UK’s Medicines & Healthcare products Regulatory Agency (MHRA) approved the use of CoverScan MD, an MRI-based technology that maps the effects of COVID-19 on several of the body’s key organs, developed by Perspectum. With 1 in 20 COVID-19 patients predicted to experience ongoing symptoms, or “Long COVID”, CoverScan MD quickly and safely provides medical professionals with the information critically needed to assess and evaluate patients.
“I’m thrilled to hear that Coverscan** has been granted approval by MHRA. I cannot stress enough how much myself and a large number of people with Long Covid* have benefitted from Coverscan. For those of us with organ damage, it has accelerated our access to treatment by informing us exactly what organs need to be examined further, while for the rest of us, it has brought us invaluable peace of mind. This is a step in the right direction, and I hope everyone who is misfortunate enough to suffer from Long Covid can benefit from this.”
Lyth Hishmeh, COVERSCAN Study Patient
‘The MHRA authorization of Coverscan is timely. UK experts and NICE are developing a COVID follow up a pathway which provides equitable access and high-quality community-based triage with rapid access to diagnostics and multi-specialty services. We have seen over 800 patients in North London, and it would be very valuable for their clinical care to be able to access COVERSCAN results.’
Dr. Melissa Heightman, Consultant Respiratory Physician, UCL, and Head of North London Long Covid care services
Perspectum’s CoverScan MD technology enables healthcare providers to identify coronavirus-related systemic organ damage through scans of patients’ hearts, lungs, livers, as well as other internal organs, and to assess the impact of SARS-CoV-2 infections. With the use of CoverScan MD, UK doctors will now have a technology to add to the arsenal of tools used to assess and evaluate patients with Long COVID, while at the same time gain a greater understanding of its symptoms and long-term impact on different organ systems.
*Long Covid affects 10-30% of people who have symptomatic infection with Sars-CoV-2 and is defined as symptomatic disease lasting longer than 12 weeks. Patients typically have extreme fatigue, chest pain, breathlessness, muscle aches, and brain fog, but there are many reported symptoms. Many of these patients have organ damage or impairment, and ways of managing this are currently being researched. Patients with Long Covid are often unable to work for long periods of time, posing a significant burden on the economy and public services.
**CoverScan MD is a software suite that provides a comprehensive, one-stop-shop assessment to detect damage in the heart, liver, lungs, kidneys, pancreas, and spleen. This single, quick MRI exam eliminates the need for multiple individual or invasive tests.
Healthcare professionals and patients are then provided with quantitative measurements and accurate information, enabling them to develop personalized treatment plans for the long-term care of patients. MHRA authorization will allow this technology to be made available to UK patients.
CECORS, INC. SHAREHOLDER UPDATE
Las Vegas, Nevada, January 14, 2021 – OTC PR WIRE – CECORS, INC. (OTC PINK: CEOS) (“CeCors” or the “Company”), is pleased to announce that the Company is transitioning into the Psychedelics Market, with a direction that includes a complete overhaul of the management team, bringing the Company to current status and delivering exciting growth for our shareholders.
The newly appointed management of PsyKey Inc. will oversee operations of CeCors as we look ahead to build a viable, sustainable, and innovative company that will become a category leader as psychedelics become legal in more and more jurisdictions. The previous officers and/or directors no longer have any relationship with CeCors, and we wish them well in their future endeavors. The Company has begun the process of becoming current in its reporting obligations with the OTC Markets, beginning with financials, completing a successful audit, and updating new director biographies accordingly.
The Acquisition Agreement between the two companies allows CeCors to purchase all outstanding shares of PsyKey Inc., a Canadian federal corporation. PsyKey Inc. will operate as a wholly-owned Canadian subsidiary of CeCors until the Company achieves current status with OTC Markets. At that point, they will look to a name change to PsyKey World. The Company has completed an Authorized Share increase of 250 million shares, for a total of 500 million Authorized Shares in order to accommodate for the acquisition. There are no outstanding convertible notes, and all shares issued in consideration for the purchase of PsyKey Inc. will be subject to standard regulatory restriction periods.
PsyKey’s vision entails:
– Valuable intellectual property portfolio
– Unique innovative delivery systems
– Product expansion
– Strong management team that values execution
“Being cognizant of the fact that most entheogenic and psychedelic companies are years away from realizing revenue, let alone profitability, we took a different approach. PsyKey Inc. is developing retail-ready nootropic-based consumables, utilizing our innovative delivery systems. This will allow us to not only generate revenue but also create brand awareness while navigating the waters of the fast-evolving psychedelic market. With our innovative delivery systems and the furthered development of our proprietary technologies, intellectual property, and patent portfolio, PsyKey Inc. is excited to build a strong position in this growing and evolving industry”. Concluded Amar Bhatal, president CeCors, Inc.
Mr. Bhatal reports the Company has updated the Nevada Secretary of State with the new officers and directors and will be completing the forms necessary to update OTC Markets for Current Status to OTC PINK.
According to Data Bridge Market Research, the psychedelic market is growing with a CAGR of 16.3% in the forecast period of 2020 to 2027 and expected to reach USD 6.8 Billion by 2027. With cannabis initially opening the doors for alternative medicines, the Psilocybin and Psychedelic Markets have garnered serious attention for the effects it has on mood, cognition and reception. Recent studies conducted on the use of psilocybin have shown the potential to relieve severe anxiety and depression.
For further information:
Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency, and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.
PAOG Publishes 2021 Cannabis Biopharmaceutical Strategic Outlook
Sandusky, OH, January 14, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today published a management outlook for 2021 on the company’s strategy to develop and monetize the cannabis assets acquired last year. The strategic outlook is included in its entirety below:
PAOG 2021 Cannabis Biopharmaceutical Strategic Outlook
PAOG is a longtime participant in the cannabis sector working on initiatives to introduce cannabis treatments as alternatives to traditional pharmaceuticals, particularly where existing pharmaceutical treatments have potentially severe secondary ramifications as is the case with opioid based treatments.
Last year, the company shifted its primary focus to the development biopharmaceutical treatments derived from cannabis.
On July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC PINK: KALY) RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method – U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.”
PAOG also acquired a of hemp cultivation business from Puration, Inc. (OTC PINK: PURA). This operation comes with existing sales activity and PAOG expects to report its first revenue from the acquisition in conjunction with the inclusion of Q4 2020 results into the overall 2020 financial report.
Since the two acquisitions, PAOG has been working diligently to develop and execute upon a strategy to monetize the assets in a manner that acheives self-sustainable operations at the same time delivering optimal shareholder value.
Toward that end, PAOG has entered into three strategic partnerships.
PAOG recently announced an engagement with Veristat, Inc., a contract research organization headquartered in Southborough Massachusetts. PAOG has engaged Veristat to assist in advancing PAOG with its proprietary Cannabidiol (CBD) extract for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) toward initiating an Investigational New Drug application (IND) with the Food and Drug Administration (FDA).
Veristat, a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years’ experience in clinical trial planning and execution, Veristat is equipped to support any development program.
Learn more about Veristat at www.veristat.com.
PAOG management anticipates a pharmaceutical development process to be a long-term endeavor. Management is committed to pursuing complimentary initiatives that have the potential to deliver revenue and profit in a shorter time frame.
PAOG has also recently engaged with the Puerto Rico Consortium for Clinical Investigation to assist PAOG with developing its proprietary Cannabidiol (CBD) extract into a nutraceutical product to provide care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).
The Puerto Rico Consortium for Clinical Investigation (PRCCI) is a not-for-profit network of top performing, high-quality research sites invested in increasing the speed and quality of clinical trials. PRCCI enhances clinical research speed and quality by driving performance and efficiencies in research sites, leveraging strategic partnerships and by establishing world-class capabilities.
PAOG is targeting revenue in 2021 resulting from its nutraceutical developments.
Learn more about PRCCI at www.prcci.org.
PAOG has also entered into a strategic partnership with PURA in conjunction with PURA’s overall initiative in Farmersville, Texas. In Farmersville, PAOG plans to build a pharmaceutical grade hemp cultivation facility and hemp extract facility. The PURA partnership includes the opportunity to work in conjunction with PURA’s partnership with Alkame Holdings, Inc. (OTC PINK: ALKM). PAOG plans to work with PURA and ALKM’s co-packing operations in the delivery of its CBD nutraceutical care solutions for those experiencing issues associated with COPD.
In a closing note to the strategic outlook, PAOG management is pleased to announce it has made the necessary application to authorize the issuance of a dividend of one share of PAOG stock to every holder of one share of PURA stock in accordance with the terms of the acquisition of the hemp cultivation business from PURA last year. PAOG anticipates announced dividend dates soon.
Learn more about PAOG at www.paogroupinc.com.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
Stars, brains, and enzymes: a celebration of MIT science
“Our topic tonight, science and discovery, lives at the heart of MIT.” In his welcoming remarks for the first virtual MIT Better World gathering, W. Eric L. Grimson, MIT chancellor for academic advancement, detailed some of the ways MIT excels as a hub of scientific research and innovation. “Institute researchers are plumbing the secrets of the universe; modeling climate at a local, regional, and global scale; striving to understand how brains and bodies give rise to cognition and mind; and racing to find treatments and cures for diseases ranging from the acute, like Covid-19, to the chronic, like cancers and maladies of the aging brain,” said Grimson, who is also the Bernard M. Gordon Professor of Medical Engineering.
Members of the MIT community from around the globe were invited to attend the MIT Better World (Science) event, held online in November, to hear from Institute leaders, faculty, students, and alumni about the pursuit of scientific knowledge. Alumni in more than 80 countries registered to attend, and the evening put a special emphasis on Canada, which is home to a group of alumni and friends who served as virtual hosts, and to which Grimson and all of the opening session speakers captured in the video above have personal ties.
Grimson’s remarks were followed by presentations from the new dean of the MIT School of Science, Nergis Mavalvala; as well as Rebecca Saxe, the John W. Jarve (1978) Professor in Brain and Cognitive Sciences and associate investigator at the McGovern Institute for Brain Research; and microbiology PhD student Linda Zhong-Johnson.
Mavalvala, the Curtis (1963) and Kathleen Marble Professor of Astrophysics, described how she and colleagues have worked to improve the sensitivity of instruments used to detect gravitational waves through LIGO—the landmark research endeavor that has revealed, among other recent discoveries, that colliding neutron stars are the “factories” in which heavy elements like gold and platinum are manufactured. Having begun the role of School of Science dean this fall, Mavalvala now takes joy in enabling discoveries across the MIT community, including those focused on our own corner of the universe. “It’s a vast world out there, and for us to make a better world, we must first understand that world. At MIT, that’s just what we do.”
Saxe, who uses brain imaging to study human social cognition, described prescient experiments on social isolation conducted by her lab between 2017 and 2019. “Sometimes we do science just out of curiosity,” said Saxe as she explained why she, former postdoc Livia Tomova, and fellow researchers pursued a project with uncertain applications — only to find themselves writing what Saxe now calls “the most timely and relevant paper in my life” in March, just as the Covid-19 pandemic triggered widespread isolation measures.
The third speaker, Linda Zhong-Johnson, discussed her PhD research in the labs of Anthony J. Sinskey, professor of biology, and Christopher A. Voigt, the Daniel I.C. Wang Professor of Advanced Biotechnology. Her goal is to reduce the amount of plastic in landfills and oceans by studying enzymes that could digest polyethylene terephthalate, or PET, the plastic used to make most water bottles. “We’re getting closer to the answer,” she said. “I’m grateful to be at MIT, where we have the mandate and resources to keep exploring.”
More virtual MIT Better World events on the topics of health and sustainability are planned for this coming February and March. Meanwhile, watch the full session (above) and a range of breakout sessions on topics such as the politics of molecular medicine and the Mars 2020 mission, and learn more about the MIT Campaign for a Better World at betterworld.mit.edu.
Ethereum, Dogecoin, Maker Price Analysis: 15 January
How are Chainlink’s whales propping up its price?
NavCoin releases its new privacy protocol, one day after Binance adds NAV to its staking program
Bitcoin Cloud Mining With Shamining: Is it Worth it? [Review]
Litecoin Regains Footing After Being Knocked Back by Resistance
Warp Finance Relaunches With ‘Additional Security’ from Chainlink
Hackers Leak Stolen Pfizer-BioNTech COVID-19 Vaccine Data
Ghana fintech startup secures $700k investment
Sophisticated Hacks Against Android, Windows Reveal Zero-Day Trove
Crypto Games May Substitute Regular Video Games in 2021
Nokian One All-Season Tire Has Life Expectancy Of 80,000 Miles
Amundi and BNY Mellon form strategic alliance
High-Severity Cisco Flaw Found in CMX Software For Retailers
The Cannabis Craze is Back in Gear (NASDAQ: SNDL) (NASDAQ: GRWG) (OTC US: MEDH) (OTC US: CRLBF)
Affinity Gaming’s SPAC Gaming & Hospitality Acquisition files for a $150 million IPO
Is Gold Still Worth Buying in the Bitcoin Age?
CISOs Prep For COVID-19 Exposure Notification in the Workplace
The Countdown is on: Bitcoin has 3 Days Before It Reaches Apex of Key Formation
Schroders appoints Global Head of Infrastructure in Private Assets
Biden to Pick Former CFTC Chair Gary Gensler as SEC Chairman: Report
Blockchain1 week ago
Is it late to have no account Cryptocurrency payment and online payment
Amb Crypto1 week ago
Cardano, Cosmos, FTX Token Price Analysis: 09 January
Amb Crypto1 week ago
Bitcoin futures volume hits an ATH of $100 billion
PR Newswire1 week ago
Kintor’s Proxalutamide (GT0918) COVID-19 Clinical Trial Shows Positive Preliminary Results in Treatment of Female Patients
Covid191 week ago
Mapped: Drone Privacy Laws Around the World
Blockchain7 days ago
Bitcoin, Altcoins Dip. Are Crypto Entering Bear Territory?
Blockchain1 week ago
Norwegian Block Exchange secures large private investment
NEWATLAS7 days ago
Lenovo AR glasses let you multi-screen virtually anywhere
Amb Crypto1 week ago
Stellar Lumens, Tron, Algorand Price Analysis: 09 January
NEWATLAS1 week ago
Externally powered implant designed to treat obesity
Amb Crypto2 days ago
Ethereum, Dogecoin, Maker Price Analysis: 15 January
SPAC Insiders1 week ago
LightJump Acquisition Corporation (LJAQU) Prices Upsized $120M IPO